spacer
home > ebr > spring 2004 > patently better - the rights and wrongs of patent protection drug discovery technology
PUBLICATIONS
European Biopharmaceutical Review

Patently Better - The Rights and Wrongs of Patent Protection Drug Discovery Technology

Whether to secure development funding, protect product licence fees or simply to stop third parties profiting from the fruits of their research, the patent is an essential business tool for firms in the biopharmaceutical field. This article looks at the essential role that patents play, and explores some important recent changes affecting the availability of patent protection.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Gareth Williams is a Patent Attorney and European Trade Mark Attorney at Marks and Clerk. Gareth obtained an honours degree in Biological Sciences from Oxford University, where he remained to complete a doctorate in Molecular Biology and Genetics researching the Y chromosome, funded as part of the Human Genome Project. He entered the patent profession in 1998 and is a qualified UK and European Patent Attorney. He has acted for clients in a variety of fields, but specialises particularly in patent work in the fields of biotechnology, medical devices, business method inventions and mechanical devices. His practice involves the drafting, filing and prosecution of patent applications worldwide, the handling of opposition and appeal work at the European Patent Office, and advice on infringement matters and general intellectual property strategy.

spacer
Gareth Williams
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioBLU® family grows

Juelich/Hannover, October 14th, 2013 – At this year’s BIOTECHNICA in Hannover, Germany Eppendorf has presented the newest members of its single-use bioreactor family BioBLU for the first time. With the new single-use bioreactor BioBLU 1c for cell culture and BioBLU 1f for microbial applications Eppendorf further extends its portfolio of rigid wall single-use bioreactors. These 1 L vessels are bridging the gap between the BioBLU 0.3 c/f mini single-use bioreactors and the larger vessels of the BioBLU family. Users in cell culture, who want to combine the advantages of single-use technology with the proven qualities of stirred-tank bioreactor design can now benefit from an unmatched portfolio of rigid wall stirred tank single-use bioreactors with working volumes from 100 mL – 40 L.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: 2nd Quarter 2014

Synergy Research Group

The Ministry of Health of Russian Federation approved 194 new clinical trials of all types including local and bioequivalence studies during the 2nd Quarter of 2014 (3% less than at the same period of the last year). The main contribution to the total number of studies was made by multinational multi-center clinical trials (MMCT) and the number of these studies stayed the same as in Q2 2013 – 81 studies. The number of bioequivalence studies (BE) decreased from 76 studies in Q2 2013 to 59 in Q2 2014, a 22% decrease from last year’s figure. The number of local clinical trials (LCT) increased from 42 in Q2 2013 to 54 clinical trials in Q2 2014.
More info >>

 
Industry Events

Pre-Filled Syringes Conference and Exhibition

28-29 January 2015, Marriott Regents Park Hotel, London, UK

Join Pre-Filled Syringes- 2015 and be part of a major networking opportunity providing intimate interaction with your peers, where you will hear case studies, presentations and round table discussions on the key issues surrounding the latest developments in the pre-filled syringes market and regulatory considerations.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement